Article(id=1291404415966114214, tenantId=1146029695717560320, journalId=1246415772164075586, issueId=1291404401374130524, articleNumber=null, orderNo=null, doi=10.13699/j.cnki.1001-6821.2025.05.004, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1730822400000, receivedDateStr=2024-11-06, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1785824405900, onlineDateStr=2026-08-04, pubDate=1742140800000, pubDateStr=2025-03-17, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1785824405900, onlineIssueDateStr=2026-08-04, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1785824405900, creator=13701087609, updateTime=1785824405900, updator=13701087609, issue=Issue{id=1291404401374130524, tenantId=1146029695717560320, journalId=1246415772164075586, year='2025', volume='41', issue='5', pageStart='601', pageEnd='750', issueExtLink='null', onlineDate='null', pubDate='1742140800000', pubDateStr='2025-03-17', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1785824402421, creator='13701087609', updateTime=1785824402421, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext=null, issueFiles=null, downloadFileDto=null}, startPage=616, endPage=620, ext={EN=ArticleExt(id=1291404419803902375, articleId=1291404415966114214, tenantId=1146029695717560320, journalId=1246415772164075586, language=EN, title=Clinical trial of nirapali combined with bevacizumab in the treatment of ovarian cancer patients, columnId=1246531407326105792, journalTitle=Chinese Journal of Clinical Pharmacology, columnName=Clinical and Basic Bridging Research, runingTitle=null, highlight=null, articleAbstract=
Objective

To observe the clinical efficacy of nilapalil toluene sulfonate capsules, bevacizumab injection, and their combination therapy for ovarian cancer, and to assess their impact on serum biomarkers and ovarian blood flow parameters.

Methods

Ovarian cancer patients were divided into three groups according to a cohort methods: Control A group, control B group, and combined group. Control A group received nilapalil toluene sulfonate capsules, 300 mg once daily for 21 days per cycle. Control B group received bevacizumab injection 7.5 mg·kg-1, administered every 3 days for 21 days per cycle. The combined group received both nilapalil toluene sulfonate capsules and bevacizumab injection following the same regimen as the control groups. All groups underwent 4 cycles of treatment. Clinical efficacy, serum tumor biomarkers, ovarian blood flow parameters, adverse drug reactions, and patient survival were compared across the three groups.

Results

A total of 31 patients in control A group, 28 patients in control B group, and 41 patients in the combined group were included. After treatment, the total effective rates for control A group, control B group, and the combined group were 70.97% (22 cases/31 cases), 71.43% (20 cases /28 cases) and 92.68% (38 cases /41 cases), respectively. The combined group showed a significantly higher effective rate compared to both control A group and control B group (all P<0.05). After treatment, the serum levels of carcinoembryonic antigen (CEA) in control A group, control B group, and the combined group were (15.26±2.33), (14.89±2.34) and (9.74±1.21) μg·L-1, respectively; and the pulsatility index (PI) were 1.35±0.24, 1.39±0.21 and 1.82±0.32, respectively. The combined group showed significant differences in these parameters compared to both control A group and control B group (all P<0.05). Adverse drug reactions in control A group mainly included gastrointestinal reactions, hair loss, and proteinuria; control B group had gastrointestinal reactions, hair loss, and muscle pain; and the combined group experienced gastrointestinal reactions, hair loss, proteinuria, and muscle pain. The overall adverse drug reaction rates in control A group, control B group, and the combined group were 25.81% (8 cases /31 cases), 25.00% (7 cases /28 cases) and 26.38% (11 cases /41 cases), respectively, with no significant difference between the groups (all P>0.05). After 12 months of follow-up, the survival rates for control A group, control B group, and the combined group were 70.97% (22 cases /31 cases), 67.86% (19 cases /28 cases) and 90.24% (37 cases /41 cases), respectively. The survival rate of the combined group was significantly higher than that of control A group and control B group (all P<0.05).

Conclusion

The combination of nilapalil toluene sulfonate capsules and bevacizumab injection in the treatment of ovarian cancer effectively reduces serum biomarker levels, improves ovarian blood flow parameters, has a low incidence of adverse drug reactions, high safety, and significantly improves patient survival.

, authors=Jia FANG, Ya XIE, authorsList=Jia FANG, Ya XIE, authorCompany=null, correspAuthors=Ya XIE, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1291404420164612520, articleId=1291404415966114214, tenantId=1146029695717560320, journalId=1246415772164075586, language=CN, title=尼拉帕利联合贝伐珠单抗治疗卵巢癌患者的临床研究, columnId=1246531407485489349, journalTitle=中国临床药理学杂志, columnName=临床与基础桥接研究, runingTitle=null, highlight=null, articleAbstract=
目的

观察甲苯磺酸尼拉帕利胶囊联合贝伐珠单抗注射液治疗卵巢癌的临床疗效,及其对血清标记物、卵巢血流参数水平的影响。

方法

将卵巢癌患者按照队列法分为对照A组、对照B组和联合组。对照A组给予甲苯磺酸尼拉帕利胶囊治疗,每次300 mg,qd,21 d为1个周期;对照B组给予贝伐珠单抗注射液7.5 mg·kg-1治疗,每3天1次,21 d为1个周期;联合组给予甲苯磺酸尼拉帕利胶囊和贝伐珠单抗注射液治疗,治疗方法和周期与对照A组和对照B组保持一致。3组患者均治疗4个周期。比较3组的临床疗效、血清肿瘤标志物、卵巢血流参数以及药物不良反应的发生情况和患者的生存情况。

结果

对照A组、对照B组和联合组分别纳入31例、28例和41例。治疗后,对照A组、对照B组和联合组的总有效率分别为70.97%(22例/31例)、71.43%(20例/28例)和92.68%(38例/41例),联合组均显著高于对照A组和对照B组(均P<0.05)。治疗后,对照A组、对照B组和联合组患者的血清癌胚抗原(CEA)分别为(15.26±2.33)、(14.89±2.34)和(9.74±1.21)μg·L-1,搏动指数(PI)分别为1.35±0.24、1.39±0.21和1.82±0.32,联合组的上述指标与对照A组和对照B组比较,在统计学上差异均有统计学意义(均P<0.05)。对照A组的药物不良反应主要有胃肠道反应、脱发、蛋白尿,对照B组的药物不良反应主要有胃肠道反应、脱发、肌肉疼痛,联合组的药物不良反应主要有胃肠道反应、脱发、蛋白尿、肌肉疼痛。对照A组、对照B组和联合组的总药物不良反应发生率分别为25.81%(8例/31例)、25.00%(7例/28例)和26.38%(11例/41例),3组组间在统计学上差异均无统计学意义(均P>0.05)。随访12个月,对照A组、对照B组和联合组生存率分别为70.97%(22例/31例)、67.86%(19例/28例)和90.24%(37例/41例),联合组生存率均显著高于对照A组和对照B组(均P<0.05)。

结论

甲苯磺酸尼拉帕利胶囊联合贝伐珠单抗注射液治疗卵巢癌能有效降低血清标记物水平,改善卵巢血流参数,且药物不良反应发生率低,安全性高,同时还能提高患者的生存率。

, authors=方佳, 谢娅, authorsList=方佳, 谢娅, authorCompany=null, correspAuthors=谢娅, authorNote=

方佳(1992-),女,主治医师,主要从事妇科临床诊疗的工作

, correspAuthorsNote=
谢娅,主任医师,硕士生导师 MP: 13783550438 E-mail:
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=C3yv4A5Sc/jP4OJuo6nU6w==, magXml=63CGOjXf0s3IW8CGUTKCxQ==, pdfUrl=null, pdf=oadF2EJn+sBpESC7E5sZkw==, pdfFileSize=1244271, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=+PFZSsXEDi+KZRW3D6Wegg==, mapNumber=null, fund=null)}, authors=[Author(id=1291404420441436589, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1291404420546294191, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, authorId=1291404420441436589, language=EN, stringName=Jia FANG, firstName=Jia, middleName=null, lastName=FANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 455000, Henan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1291404420621791664, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, authorId=1291404420441436589, language=CN, stringName=方佳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=郑州大学 第一附属医院 妇科,河南 郑州 455000, bio={"content":"

方佳(1992-),女,主治医师,主要从事妇科临床诊疗的工作

"}, bioImg=null, bioContent=

方佳(1992-),女,主治医师,主要从事妇科临床诊疗的工作

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1291404420361744809, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, xref=null, ext=[AuthorCompanyExt(id=1291404420370133418, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, companyId=1291404420361744809, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 455000, Henan Province, China), AuthorCompanyExt(id=1291404420378522027, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, companyId=1291404420361744809, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=郑州大学 第一附属医院 妇科,河南 郑州 455000)])]), Author(id=1291404420684706226, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=xieya838@126.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1291404420789563828, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, authorId=1291404420684706226, language=EN, stringName=Ya XIE, firstName=Ya, middleName=null, lastName=XIE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 455000, Henan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1291404420852478389, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, authorId=1291404420684706226, language=CN, stringName=谢娅, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=郑州大学 第一附属医院 妇科,河南 郑州 455000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1291404420361744809, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, xref=null, ext=[AuthorCompanyExt(id=1291404420370133418, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, companyId=1291404420361744809, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 455000, Henan Province, China), AuthorCompanyExt(id=1291404420378522027, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, companyId=1291404420361744809, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=郑州大学 第一附属医院 妇科,河南 郑州 455000)])])], keywords=[Keyword(id=1291404420982501814, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, language=EN, orderNo=1, keyword=nilapalil toluene sulfonate capsules), Keyword(id=1291404421070582199, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, language=EN, orderNo=2, keyword=bevacizumab injection), Keyword(id=1291404421150273976, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, language=EN, orderNo=3, keyword=ovarian cancer), Keyword(id=1291404421204799929, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, language=EN, orderNo=4, keyword=tumor markers), Keyword(id=1291404421271908794, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, language=EN, orderNo=5, keyword=hemodynamics), Keyword(id=1291404421334823355, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, language=CN, orderNo=1, keyword=甲苯磺酸尼拉帕利胶囊), Keyword(id=1291404421410320828, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, language=CN, orderNo=2, keyword=贝伐珠单抗注射液), Keyword(id=1291404421460652477, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, language=CN, orderNo=3, keyword=卵巢癌), Keyword(id=1291404421569704382, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, language=CN, orderNo=4, keyword=肿瘤标志物), Keyword(id=1291404421653590463, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, language=CN, orderNo=5, keyword=血流动力学)], refs=null, funds=null, companyList=[AuthorCompany(id=1291404420361744809, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, xref=null, ext=[AuthorCompanyExt(id=1291404420370133418, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, companyId=1291404420361744809, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 455000, Henan Province, China), AuthorCompanyExt(id=1291404420378522027, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, companyId=1291404420361744809, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=郑州大学 第一附属医院 妇科,河南 郑州 455000)])], figs=null, attaches=null, journal=Journal(id=1246415058658443328, delFlag=0, nameCn=中国临床药理学杂志, nameEn=Chinese Journal of Clinical Pharmacology, nameHistory1=null, nameHistory2=null, issn=1001-6821, eissn=null, cn=11-2220/R, coden=null, periodic=3, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=8cEfS7jvj/ukyhKVOMJePA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Clinical Pharmacology, journalRemark=null, publicationField=null, createdTime=1775098107259, updatedTime=1784020014723, createdBy=18614031015, updatedBy=13041195026, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Life Sciences, subjectName=null, subjectCodeEn=Life Sciences, subjectNameEn=null, picCn=8cEfS7jvj/ukyhKVOMJePA==, picEn=cQ12tu98gbNetbFuefeYGg==, jcr=null, cjcr=null, exts=[JournalExt(id=1283836250926859016, language=CN, name=中国临床药理学杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1784020014745, updatedTime=1784020014745, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=https://lcylauthor.cast.org.cn/webm, submissionEditorUrl=https://lcyleditor.cast.org.cn/webm, submissionReviewUrl=https://lcylauthor.cast.org.cn/webm, submissionCeEditorUrl=https://lcyleditor.cast.org.cn/webm, submissionAeEditorUrl=https://lcyleditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1283836250981384969, language=EN, name=Chinese Journal of Clinical Pharmacology, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1784020014758, updatedTime=1784020014758, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=https://lcylauthor.cast.org.cn/webm, submissionEditorUrl=https://lcyleditor.cast.org.cn/webm, submissionReviewUrl=https://lcylauthor.cast.org.cn/webm, submissionCeEditorUrl=https://lcyleditor.cast.org.cn/webm, submissionAeEditorUrl=https://lcyleditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1246415772164075586, websiteList=[Website(id=1246421196657546140, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1246415772164075586, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zglcylxzz/CN, language=CN, createTime=1775099570670, createBy=18614031015, updateTime=1775099747371, updateBy=18614031015, name=中国临床药理学杂志-中文, tplId=1146099689490845704, title=中国临床药理学杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1246422027293316008, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196657546140, code=articleTextType, value=kx, createTime=1775099768708, updateTime=1775099768708, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422027268150181, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196657546140, code=banner, value=null, createTime=1775099768702, updateTime=1775099768702, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422027310093227, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196657546140, code=grayFlag, value=0, createTime=1775099768712, updateTime=1775099768712, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422027259761572, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196657546140, code=logo, value=https://castjournals.cast.org.cn/joweb/zglcylxzz/CN/file/pic?fileId=KeUk4pyVjfIIkOq40uZX0Q==, createTime=1775099768700, updateTime=1775099768700, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422027322676141, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196657546140, code=minRunFlag, value=0, createTime=1775099768715, updateTime=1775099768715, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422027284927399, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196657546140, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zglcylxzz/CN/file/pic, createTime=1775099768706, updateTime=1775099768706, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422027318481836, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196657546140, code=silenceFlag, value=0, createTime=1775099768714, updateTime=1775099768714, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422027276538790, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196657546140, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1775099768704, updateTime=1775099768704, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422027297510313, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196657546140, code=themeColor, value=null, createTime=1775099768709, updateTime=1775099768709, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422027305898922, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196657546140, code=themeStyle, value=null, createTime=1775099768711, updateTime=1775099768711, creator=18614031015, updator=18614031015)]), Website(id=1246421196871455649, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1246415772164075586, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zglcylxzz/EN, language=EN, createTime=1775099570720, createBy=18614031015, updateTime=1775099757298, updateBy=18614031015, name=中国临床药理学杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Clinical Pharmacology, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1246422058998059954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196871455649, code=articleTextType, value=kx, createTime=1775099776267, updateTime=1775099776267, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422058977088431, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196871455649, code=banner, value=null, createTime=1775099776262, updateTime=1775099776262, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422059014837173, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196871455649, code=grayFlag, value=0, createTime=1775099776271, updateTime=1775099776271, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422058968699822, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196871455649, code=logo, value=https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/file/pic?fileId=KeUk4pyVjfIIkOq40uZX0Q==, createTime=1775099776260, updateTime=1775099776260, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422059031614391, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196871455649, code=minRunFlag, value=0, createTime=1775099776275, updateTime=1775099776275, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422058993865649, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196871455649, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/file/pic, createTime=1775099776266, updateTime=1775099776266, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422059023225782, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196871455649, code=silenceFlag, value=0, createTime=1775099776273, updateTime=1775099776273, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422058985477040, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196871455649, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1775099776264, updateTime=1775099776264, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422059002254259, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196871455649, code=themeColor, value=null, createTime=1775099776268, updateTime=1775099776268, creator=18614031015, updator=18614031015), WebsiteProps(id=1246422059010642868, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1246421196871455649, code=themeStyle, value=null, createTime=1775099776270, updateTime=1775099776270, creator=18614031015, updator=18614031015)])], journalTitle=中国临床药理学杂志, weixinUrl=null, journalUrl=null, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Clinical Pharmacology, journalPhotoCn=8cEfS7jvj/ukyhKVOMJePA==, journalPhotoEn=cQ12tu98gbNetbFuefeYGg==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zglcylxzz/CN/10.13699/j.cnki.1001-6821.2025.05.004, detailUrlEn=https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2025.05.004, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zglcylxzz/CN/PDF/10.13699/j.cnki.1001-6821.2025.05.004, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/PDF/10.13699/j.cnki.1001-6821.2025.05.004, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1742140800000, fullTextJson=null, articleText=null, reference=null)
收藏切换
尼拉帕利联合贝伐珠单抗治疗卵巢癌患者的临床研究
收藏切换
PDF下载
方佳 , 谢娅
中国临床药理学杂志 | 临床与基础桥接研究 2025,41(5): 616-620
收起
收藏切换
中国临床药理学杂志 |临床与基础桥接研究 2025 , 41 (5) : 616 -620
尼拉帕利联合贝伐珠单抗治疗卵巢癌患者的临床研究
全屏
[Author(id=1291404420441436589, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1291404420546294191, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, authorId=1291404420441436589, language=EN, stringName=Jia FANG, firstName=Jia, middleName=null, lastName=FANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 455000, Henan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1291404420621791664, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, authorId=1291404420441436589, language=CN, stringName=方佳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=郑州大学 第一附属医院 妇科,河南 郑州 455000, bio={"content":"

方佳(1992-),女,主治医师,主要从事妇科临床诊疗的工作

"}, bioImg=null, bioContent=

方佳(1992-),女,主治医师,主要从事妇科临床诊疗的工作

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1291404420361744809, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, xref=null, ext=[AuthorCompanyExt(id=1291404420370133418, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, companyId=1291404420361744809, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 455000, Henan Province, China), AuthorCompanyExt(id=1291404420378522027, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, companyId=1291404420361744809, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=郑州大学 第一附属医院 妇科,河南 郑州 455000)])]), Author(id=1291404420684706226, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=xieya838@126.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1291404420789563828, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, authorId=1291404420684706226, language=EN, stringName=Ya XIE, firstName=Ya, middleName=null, lastName=XIE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 455000, Henan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1291404420852478389, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, authorId=1291404420684706226, language=CN, stringName=谢娅, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=郑州大学 第一附属医院 妇科,河南 郑州 455000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1291404420361744809, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, xref=null, ext=[AuthorCompanyExt(id=1291404420370133418, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, companyId=1291404420361744809, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 455000, Henan Province, China), AuthorCompanyExt(id=1291404420378522027, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1291404415966114214, companyId=1291404420361744809, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=郑州大学 第一附属医院 妇科,河南 郑州 455000)])])]
方佳, 谢娅
作者信息
  • 郑州大学 第一附属医院 妇科,河南 郑州 455000
通讯作者:
谢娅,主任医师,硕士生导师 MP: 13783550438 E-mail:
作者简介:

方佳(1992-),女,主治医师,主要从事妇科临床诊疗的工作

Clinical trial of nirapali combined with bevacizumab in the treatment of ovarian cancer patients
Jia FANG, Ya XIE
Affiliations
  • Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 455000, Henan Province, China
出版时间: 2025-03-17 doi: 10.13699/j.cnki.1001-6821.2025.05.004
文章导航
收藏切换
目的

观察甲苯磺酸尼拉帕利胶囊联合贝伐珠单抗注射液治疗卵巢癌的临床疗效,及其对血清标记物、卵巢血流参数水平的影响。

方法

将卵巢癌患者按照队列法分为对照A组、对照B组和联合组。对照A组给予甲苯磺酸尼拉帕利胶囊治疗,每次300 mg,qd,21 d为1个周期;对照B组给予贝伐珠单抗注射液7.5 mg·kg-1治疗,每3天1次,21 d为1个周期;联合组给予甲苯磺酸尼拉帕利胶囊和贝伐珠单抗注射液治疗,治疗方法和周期与对照A组和对照B组保持一致。3组患者均治疗4个周期。比较3组的临床疗效、血清肿瘤标志物、卵巢血流参数以及药物不良反应的发生情况和患者的生存情况。

结果

对照A组、对照B组和联合组分别纳入31例、28例和41例。治疗后,对照A组、对照B组和联合组的总有效率分别为70.97%(22例/31例)、71.43%(20例/28例)和92.68%(38例/41例),联合组均显著高于对照A组和对照B组(均P<0.05)。治疗后,对照A组、对照B组和联合组患者的血清癌胚抗原(CEA)分别为(15.26±2.33)、(14.89±2.34)和(9.74±1.21)μg·L-1,搏动指数(PI)分别为1.35±0.24、1.39±0.21和1.82±0.32,联合组的上述指标与对照A组和对照B组比较,在统计学上差异均有统计学意义(均P<0.05)。对照A组的药物不良反应主要有胃肠道反应、脱发、蛋白尿,对照B组的药物不良反应主要有胃肠道反应、脱发、肌肉疼痛,联合组的药物不良反应主要有胃肠道反应、脱发、蛋白尿、肌肉疼痛。对照A组、对照B组和联合组的总药物不良反应发生率分别为25.81%(8例/31例)、25.00%(7例/28例)和26.38%(11例/41例),3组组间在统计学上差异均无统计学意义(均P>0.05)。随访12个月,对照A组、对照B组和联合组生存率分别为70.97%(22例/31例)、67.86%(19例/28例)和90.24%(37例/41例),联合组生存率均显著高于对照A组和对照B组(均P<0.05)。

结论

甲苯磺酸尼拉帕利胶囊联合贝伐珠单抗注射液治疗卵巢癌能有效降低血清标记物水平,改善卵巢血流参数,且药物不良反应发生率低,安全性高,同时还能提高患者的生存率。

甲苯磺酸尼拉帕利胶囊  /  贝伐珠单抗注射液  /  卵巢癌  /  肿瘤标志物  /  血流动力学
Objective

To observe the clinical efficacy of nilapalil toluene sulfonate capsules, bevacizumab injection, and their combination therapy for ovarian cancer, and to assess their impact on serum biomarkers and ovarian blood flow parameters.

Methods

Ovarian cancer patients were divided into three groups according to a cohort methods: Control A group, control B group, and combined group. Control A group received nilapalil toluene sulfonate capsules, 300 mg once daily for 21 days per cycle. Control B group received bevacizumab injection 7.5 mg·kg-1, administered every 3 days for 21 days per cycle. The combined group received both nilapalil toluene sulfonate capsules and bevacizumab injection following the same regimen as the control groups. All groups underwent 4 cycles of treatment. Clinical efficacy, serum tumor biomarkers, ovarian blood flow parameters, adverse drug reactions, and patient survival were compared across the three groups.

Results

A total of 31 patients in control A group, 28 patients in control B group, and 41 patients in the combined group were included. After treatment, the total effective rates for control A group, control B group, and the combined group were 70.97% (22 cases/31 cases), 71.43% (20 cases /28 cases) and 92.68% (38 cases /41 cases), respectively. The combined group showed a significantly higher effective rate compared to both control A group and control B group (all P<0.05). After treatment, the serum levels of carcinoembryonic antigen (CEA) in control A group, control B group, and the combined group were (15.26±2.33), (14.89±2.34) and (9.74±1.21) μg·L-1, respectively; and the pulsatility index (PI) were 1.35±0.24, 1.39±0.21 and 1.82±0.32, respectively. The combined group showed significant differences in these parameters compared to both control A group and control B group (all P<0.05). Adverse drug reactions in control A group mainly included gastrointestinal reactions, hair loss, and proteinuria; control B group had gastrointestinal reactions, hair loss, and muscle pain; and the combined group experienced gastrointestinal reactions, hair loss, proteinuria, and muscle pain. The overall adverse drug reaction rates in control A group, control B group, and the combined group were 25.81% (8 cases /31 cases), 25.00% (7 cases /28 cases) and 26.38% (11 cases /41 cases), respectively, with no significant difference between the groups (all P>0.05). After 12 months of follow-up, the survival rates for control A group, control B group, and the combined group were 70.97% (22 cases /31 cases), 67.86% (19 cases /28 cases) and 90.24% (37 cases /41 cases), respectively. The survival rate of the combined group was significantly higher than that of control A group and control B group (all P<0.05).

Conclusion

The combination of nilapalil toluene sulfonate capsules and bevacizumab injection in the treatment of ovarian cancer effectively reduces serum biomarker levels, improves ovarian blood flow parameters, has a low incidence of adverse drug reactions, high safety, and significantly improves patient survival.

nilapalil toluene sulfonate capsules  /  bevacizumab injection  /  ovarian cancer  /  tumor markers  /  hemodynamics
方佳, 谢娅. 尼拉帕利联合贝伐珠单抗治疗卵巢癌患者的临床研究. 中国临床药理学杂志, 2025 , 41 (5) : 616 -620 . DOI: 10.13699/j.cnki.1001-6821.2025.05.004
Jia FANG, Ya XIE. Clinical trial of nirapali combined with bevacizumab in the treatment of ovarian cancer patients[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (5) : 616 -620 . DOI: 10.13699/j.cnki.1001-6821.2025.05.004

参考文献 引证文献
排序方式:
2025年第41卷第5期
PDF下载
3
1
引用本文
BibTeX
文章信息
doi: 10.13699/j.cnki.1001-6821.2025.05.004
  • 接收时间:2024-11-06
  • 首发时间:2026-08-04
  • 出版时间:2025-03-17
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-11-06
基金
作者信息
    郑州大学 第一附属医院 妇科,河南 郑州 455000

通讯作者:

谢娅,主任医师,硕士生导师 MP: 13783550438 E-mail:
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zglcylxzz/CN/10.13699/j.cnki.1001-6821.2025.05.004
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏